Sign in to continue:

Thursday, January 29th, 2026

Global Markets Retreat in November 2025 Amid Tech Valuation Concerns and US Economic Uncertainty

Broker: OCBC Investment Research
Date of Report: 18 November 2025
Excerpt from OCBC Investment Research report.

  • Global markets experienced a broad sell-off, driven by concerns over stretched tech valuations, upcoming major earnings, and a delayed US jobs report.
  • US stocks fell sharply, with both S&P 500 and Nasdaq closing below their 50-day moving averages, while European and Asian markets also declined amid worries about tech and geopolitics.
  • Investors are bracing for key US economic data and retail earnings as signals for future market direction, while interest rates are now expected to remain higher for longer into 2025.
  • Singapore’s Straits Times Index saw a slight dip, with mixed sector performance and lower trading volume; latest analyst reports feature positive outlooks on several local stocks and REITs.
  • OCBC’s coverage highlights top STI stocks by market cap, with recommendations and key financial metrics for leading Singapore companies.

above is an excerpt from a report by OCBC Investment Research. Clients of OCBC Investment Research can be the first to access the full report from the OCBC Investment Research website : https://www.ocbc.com/personal-banking/investments/investment-research

Keppel DC REIT to Acquire Second Japan Data Centre: DPU Accretive Growth and Portfolio Expansion in 2025

CGS International Report Date: September 23, 2025 Keppel DC REIT Accelerates Asia-Pacific Growth with Major Japan Data Centre Acquisition: A Comprehensive REIT Sector Analysis Introduction: CGS International’s Strategic Review of Keppel DC REIT and...

Senoko Energy Gains Sembcorp Utilities as New Stakeholder with 30% Acquisition

Date of Report: September 30, 2024Broker Name: CGS International Securities Sembcorp Utilities Acquires 30% Stake in Senoko EnergySenoko Energy, one of Singapore’s largest power generation companies, has seen a strategic investment from Sembcorp Utilities....

VISEN Pharmaceuticals’ HK$672 Million IPO: Pioneering Endocrine Therapies in Hong Kong’s Biotech Boom

​Visen Pharmaceuticals, a biopharmaceutical company specializing in endocrinology treatments in China, is set to list on the Hong Kong Stock Exchange under the ticker 02561.HK. The IPO is scheduled for March 21, 2025, aiming...